Sorrento Announces FDA Authorization to Proceed With Phase 1 Study Of Intranasal STI-9199 (COVISHIELD), a Potent Neutralization Antibody Against Covid-19 Viruses
March 02, 2022 11:24 ET
|
Sorrento Therapeutics, Inc.
FDA granted IND clearance today for STI-9199 (COVISHIELD™) for a Phase 1 safety and pharmacokinetic study in healthy volunteers.Initial trials are expected to be followed by a multinational Phase 2/3...
Sorrento Announces COVISHIELD (STI-9167) Antibody Strongly Neutralizes BA.2 Omicron Sublineage Virus as Well as BA.1 and BA.1+R346k Omicron Viruses
February 22, 2022 09:00 ET
|
Sorrento Therapeutics, Inc.
STI-9167 neutralizing antibody (nAb) maintains high neutralization potency against the recently emerging Omicron sublineage BA.2 as was previously demonstrated for the Omicron sublineage BA.1 viruses,...
Sorrento Announces That It Has Acquired a Majority Ownership in Diagnostic Manufacturer Zhengzhou Fortune Bioscience in Response to Increasing Worldwide Demand For COVISTIX™
February 17, 2022 13:02 ET
|
Sorrento Therapeutics, Inc.
COVISTIX is a highly sensitive and rapid antigen detection test for SARS-CoV-2 and its major variants of concern (VOCs), including the Omicron variant.COVISTIX has an enhanced sensitivity in detecting...
Sorrento Completes Acquisition of Virex Health, Will Commercialize Next-Generation at-Home Diagnostic Testing That Rivals PCR-Level Sensitivity for Daily Covid-19 Tests and Early Cancer Diagnosis
February 01, 2022 09:00 ET
|
Sorrento Therapeutics, Inc.
Virex Health, Inc. is a Boston, Massachusetts company that has developed a powerful, broadly applicable at-home diagnostic platform (“Virex Technology”).Virex Technology, invented and developed by...
Sorrento Announces Its Oral SARS-CoV-2 Main Protease (Mpro) Inhibitor, STI-1558, Strongly Neutralizes Omicron
January 28, 2022 09:00 ET
|
Sorrento Therapeutics, Inc.
STI-1558, a novel oral Mpro inhibitor, effectively inhibits Omicron virus entry and replication in cells.STI-1558 is orally bioavailable with improved human liver microsomal stability to avoid using...
Sorrento Receives Purchase Order for 10 Million Covistix Tests From Its Subsidiary Sorrento Mexico for February Delivery in Mexico
January 24, 2022 09:00 ET
|
Sorrento Therapeutics, Inc.
As COVID-19 cases spike in Mexico, Sorrento Therapeutics Mexico (“Sorrento Mexico”) won the first tender offer in 2022 by the Mexico City Government for COVISTIX tests, which were delivered in the...
Sorrento Therapeutics Announces Covishield (Sti-9167), a Broad-Spectrum Neutralizing Antibody, Potently Neutralizes Omicron and Omicron (+R346k) Variants of Sars-Cov-2
January 21, 2022 07:00 ET
|
Sorrento Therapeutics, Inc.
COVISHIELD (STI-9167) neutralizing antibody (nAb) was discovered by scientists from the Icahn School of Medicine at Mount Sinai (“Icahn Mount Sinai”) and further optimized and engineered by Sorrento...
Sorrento Announces That Sorrento Mexico Has Sold Out of One Million COVISTIX Tests Last Week in Mexico
January 19, 2022 14:26 ET
|
Sorrento Therapeutics, Inc.
Sorrento Therapeutics Mexico (“Sorrento Mexico”) distributed last week approximately one million COVISTIX tests in Mexico.Additional millions of COVISTIX tests are scheduled to be delivered to meet...
Sorrento Announces Completion of Enrollment in US Phase 2 Clinical Trial for COVI-DROPS and Achievement of Interim Analysis Threshold in the UK
January 19, 2022 10:35 ET
|
Sorrento Therapeutics, Inc.
COVID-19 patients with newly diagnosed SARS-CoV-2 infections were treated in these randomized, double-blind, placebo-controlled Phase 2 trials in the US and UK.COVI-DROPS™ neutralizing antibody was...
Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Clinical Trial of COVI-MSC in COVID-19 Patients With Persistent Pulmonary Compromise After Recovery (Long-Hauler)
January 18, 2022 09:00 ET
|
Sorrento Therapeutics, Inc.
Brazil Phase 2 Pulmonary Long-Hauler clinical trial of COVI-MSC is now authorized to proceed.The study will compare therapy using mesenchymal stromal cells to placebo (and standard of care) in 60...